Public Market Listing
Live quotes, historical charts, and market capitalization for Otsuka Holdings are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(23 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule | SchizophreniaBipolar Disorder | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Major Depressive DisorderSchizophreniaBipolar Disorder | |
Bempedoic acid(Nexletol) | Approved | ATP citrate lyaseSmall molecule | Atherosclerotic Cardiovascular Disease |
Bempedoic acid/ezetimibe(Nexlizet) | Approved | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule | Atherosclerotic Cardiovascular Disease |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia | |
Centanafadine(Simtriyo) | Approved | Serotonin/norepinephrine/dopamine transporterSmall molecule | Attention Deficit Hyperactivity Disorder |
| Approved | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Small molecule | Acute Myeloid LeukemiaMyelodysplastic Syndromes | |
difamilast(Moizerto / Adquey) | Approved | PDE4Small molecule | Atopic Dermatitis |
Donidalorsen(Dawnzera) | Approved | Prekallikrein (PKK) mRNARNA / oligonucleotide | Hereditary Angioedema |
| Approved | CGRP ligandMonoclonal antibody | Migraine | |
Ponatinib(ICLUSIG) | Approved | BCR-ABL (including T315I)Small molecule | Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia |
rotigotine(Neupro) | Approved | Dopamine receptorsSmall molecule | Parkinson's Disease |
Sacubitril/valsartan(Entresto) | Approved | Neprilysin + Angiotensin II receptor (dual)Small molecule | HypertensionHeart Failure |
| Approved | Vasopressin V2 receptorSmall molecule | Autosomal Dominant Polycystic Kidney Disease | |
Voclosporin(Lupkynis) | Approved | Calcineurin · Cyclophilin A (leading to calcineurin inhibition)Small molecule | Systemic Lupus ErythematosusLupus Nephritis |
Discontinued programmes (2)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (8)
February 2027 (1)
What to watch
May 2027 (1)
What to watch
August 2027 (2)
September 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (5)
February 2028 (1)
What to watch
March 2028 (1)
October 2028 (1)
2029 (2)
May 2029 (1)
June 2029 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $4.0B | $523M | $3.4B | — | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $16.5B | $2.4B | $3.4B | — | report ↗ |
Otsuka Pharmaceutical reported revenue of $16,498.34M, up 7.1% YoY, R&D spend of $2,357.84M, up 13.5% YoY, and cash and equivalents of $3,413.87M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text